Pharma engagement shifts from reach to relevance

Tern plc

Pharmaceutical marketing is changing because patients are researching earlier, using more digital channels and arriving at healthcare conversations with stronger opinions about their options.

The effectiveness of pharma engagement is increasingly tied to timing, relevance and message quality. Reaching patients is no longer enough. Companies need to understand what patients are thinking, what concerns are shaping their decisions and where communication can support action.

The original direct-to-consumer and direct-to-patient models still have value, but they do not fully reflect how people now make healthcare decisions. Patients may see social content, read online discussions, use AI tools, compare treatment options and speak to healthcare professionals, all within the same decision-making process. These touchpoints are connected, even if pharma campaigns are often planned separately.

This is where message resonance becomes commercially important. A message works when it reflects what patients actually care about at the moment they need support. That may include confidence, side effects, treatment expectations, cost, access or how to discuss an option with a healthcare professional. Poorly timed or generic content risks being ignored. Relevant messaging can help move patients from interest to informed action.

In markets like this, patients are not waiting passively for information. They are actively shaping their views before they enter clinical conversations. That changes the role of pharma communication from broad awareness to more precise engagement across the full journey.

For life sciences companies, the practical challenge is to connect patient insight with commercial execution. That means understanding the language patients use, the questions they ask and the points where confusion or hesitation appear. It also means aligning patient communication with healthcare professional engagement so that messages are consistent rather than fragmented.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Device Authority addresses security risks as AI takes control of physical machines

Device Authority's KeyScaler platform supports secure AI-driven automation by helping organisations authenticate connected machines, protect device identities and control access to physical equipment.

Talking Medicines examines factors influencing prescribing decisions

Talking Medicines explains how healthcare professional conversations, clinical considerations and treatment perceptions can provide pharmaceutical companies with deeper insight into prescribing intent beyond traditional campaign metrics.

What HCPs say could reveal prescribing intent

Talking Medicines is using AI to analyse HCP conversations and identify the clinical and practical factors that may influence prescribing intent.

AI control of machines raises new security questions

AI is gaining the ability to control physical equipment, but establishing that machines are genuine, authorised and secure will be an important part of making this technology safe to deploy.

CAR-T therapy brings new approach to multiple myeloma treatment

CAR-T therapy is being used in multiple myeloma and is being studied earlier in the treatment pathway, with research focused on improving durability, safety and access.

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

Search